Intensity modulated radiation therapy with simultaneous integrated boost based dose escalation on neoadjuvant chemoradiation therapy for locally advanced distal esophageal adenocarcinoma

Table 1 Characteristics of 17 patients

Characteristic	Value
Mean age (range)	65 yr (45-76)
Men/women (n)	14/3
ECOG PS (n)
0	14
1	3
2	0
3	0
T stage (n)
T1	0
T2	2
T3	15
T4	0
N stage (n)
N0	12
N1	5
Concurrent chemotherapy (n)
5-FU/cisplatin	11
Carboplatin/Taxel	6
Tumor location: < 35 cm/> 35 cm (n)	14/3
Mean gross tumor volume (cm3) (range)	43.7 (33.3-62.4)
Mean clinical tumor volume (cm3) (range)	503.2 (419.3-577.1)

ECOG PS: Eastern Cooperative Oncology Group performance status; 5-FU: 5-fluorouracil.

Table 2 Pathological staging post simultaneous integrated boost based neoadjuvant chemoradiation

Pathological staging	Patient n (%)
ypT
0	8 (47)
1	4 (23)
2	3 (18)
3	2 (12)
4	0
ypN
0	13 (76.5)
1	4 (23.5)

Table 3 Postoperative toxicity after neoadjuvant treatment followed by surgery

Pulmonary	5
Pneumonia	3
Pneumonitis	2
Cardiac1	1
Surgery related	6
Anastomotic leakage	4
Anastomotic stricture	1
Wound infection	1
Death within admission	0

¹Cardiac toxicities include heart attack, cardiac rhythm changes, pericardia effusion.

Table 4 Survival by prognostic factor

		Overall survival (%)
		1 yr	3 yr	P value
Sex
Female	2	100 (2)	100 (2)	0.017584
Male	15	73 (11)	47 (7)
Tumor size
> 3 cm	9	78 (7)	44 (4)	0.34649
< 3 cm	6	83 (5)	67 (4)
Unknown	2	50 (1)	50 (1)
Concurrent chemo
5-FU based	11	82 (9)	55 (6)	0.078225
Cis based	6	83 (5)	50 (3)
Tumor configuration
> 180 cm	8	63 (5)	50 (4)	0.382319
< 180 cm	9	89 (8)	55 (5)
Node status
Negative	13	85 (11)	62 (8)	0.009262
Positive	4	75 (3)	25 (1)
Location of primary tumor
20-35 cm	12	83 (10)	58 (7)	0.024229
> 35 ~	5	80 (4)	40 (2)
Total	17	82 (14)	53 (9)

5-FU: 5-fluorouracil.